ProMetic Life Sciences Inc. (PLI) 2008年年度报告「TSX」.pdf

1、ProMetic Life Sciences Inc.Annual ReportSignifi cant Events of 2008 2Message to Shareholders 4ProMetics Technologies 9MD&A 17Consolidated Financial Statements 35Front Cover Illustration These stylized red blood cells in a DNA confi guration signify the focus of the various businesses and research pu

2、rsuits of ProMetic Life Sciences Inc.This graphic represents a clear evolution of that in last year s Annual Report,refl ective of the progression of ProMetic over the past 12 months.The Company is involved in diverse activities related to blood.Its technologies are used to extract proteins from pla

3、sma and remove pathogens from blood,while its principal therapeutics are aimed at treating blood-related disorders.We areProgressiveEfficientInnovativeCost EffectiveProMetic has developed and now manufactures innovative bioseparation products which are used globally by an increasing number of top-ti

4、er pharmaceutical companies.ProMetic has become a recognized world leader for introducing a revolutionary plasma fractionation process,which is being increasingly adopted as a replacement for a decades-old legacy system.The efficiencies of ProMetics biopharmaceutical purification and pathogen remova

5、l technologies are recognized as state-of-the-art contributions to high-value drug manufacturing and the safety of transfused human blood.ProMetics protein extraction technology assists the manufacturers of a wide range of blood-derived products to achieve higher yields,with fewer processing steps a

6、nd at lower costs.ProMetic has discovered synthetic compounds with unique properties for the treatment of blood disorders,and applications in hematology,nephrology and oncology.|ProMetic Life Sciences Inc.1Signifi cantProMetic and its partner MacoPharma SA announced successful completion of two huma